What Are the Classifications of Myelodysplastic Syndromes?

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

Myelodysplastic syndromes are generally classified into “lower risk MDS” and “higher risk MDS.” Your physician can tell you which classification you fall under based on the characteristics of your disease. The three primary characteristics are percent of marrow blasts (immature cells), chromosome abnormalities, and blood counts (platelets, red cells, and white cells). 

In general, if you have blasts that are less than 10 percent of total blood cells, you fall in the lower risk category. Blasts equal to or above 10 percent, many abnormal chromosomes, and low platelet and red and white blood cell counts put you in the higher risk category. 

The most commonly used classification system is called the International Prognostic Scoring System (IPSS). The table below shows how your risk category correlates to the IPSS score. A score of 0 to 1 is in the lower risk category, whereas a score above 1 places you in the higher risk category. 

 

IPSS Risk 

Score 

Average Survival 

Low 

0 

5-6 years 

Intermediate 1 

0.5-1 

3-4 years 

Intermediate 2 

1.5-2 

1-1.5 years 

High 

= 2.5 

4-6 months 

 

These categories help determine the type of treatment you will receive. 

 

This content was last modified on August 11, 2007 .
Latest Cancer News
Radiofrequency Ablation Effective For Small Renal Cell Carcinoma and Other Masses

March 11, 2010 — Researchers from the M. D. Anderson Cancer Center have reported that radiofrequency ablation (RFA) is effective treatment for patients with renal masses, including renal cell carcinoma (RCC). The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium March 5-7 in San Francisco.

Single-dose Neulasta® as Effective as Multiple-dose Neupogen® in Children with Sarcoma

March 11, 2010 — Researchers involved in an international multicenter randomized trial have reported that single-dose Neulasta® (pegfilgrastim) is as effective as multiple-dose Neupogen® (filagrastim) for support of children receiving intensive chemotherapy for previously treated sarcoma. The details of this study were published in the March 10, 2010 issue of the Journal of Clinical Oncology.

Updated Survival Data on Provenge® for Treatment of Hormone Refractory Prostate Cancer Presented

March 11, 2010 — Researchers affiliated with the IMPACT trial have reported that additional follow-up and more analyses demonstrate a clear survival advantage of Provenge® (sipuleucel-T) versus placebo in men with hormone-refractory prostate cancer. The details of this study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco between March 5 and 7.

Select news items provided by Reuters Health